Get started
CollPlant Biotechnologies Ltd.CollPlant Biotechnologies Ltd.CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CLGN chart


Full chart

CLGN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪44.90 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.53 USD
Net income (FY)
‪−7.02 M‬ USD
Revenue (FY)
‪10.96 M‬ USD
Shares float
‪7.88 M‬
Beta (1Y)
0.82

Employees


Employees (FY)
75
Change (1Y)
+2 +2.74%
Revenue / Employee (1Y)
‪146.12 K‬ USD
Net income / Employee (1Y)
‪−93.59 K‬ USD

About CollPlant Biotechnologies Ltd.


Sector
Health Technology
Industry
Medical Specialties
CEO
Yehiel Tal
Website
collplant.com
Headquarters
Rehovot
Founded
2004
ISIN
IL0004960188
FIGI
BBG008754R36
CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CLGN news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CLGN is 3.92 USD — it has increased by 3.43% in the past 24 hours. Watch CollPlant Biotechnologies Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange CollPlant Biotechnologies Ltd. stocks are traded under the ticker CLGN.
CLGN stock has risen by 7.69% compared to the previous week, the month change is a −15.33% fall, over the last year CollPlant Biotechnologies Ltd. has showed a −30.62% decrease.
We've gathered analysts' opinions on CollPlant Biotechnologies Ltd. future price: according to them, CLGN price has a max estimate of 14.00 USD and a min estimate of 11.00 USD. Watch CLGN chart and read a more detailed CollPlant Biotechnologies Ltd. stock forecast: see what analysts think of CollPlant Biotechnologies Ltd. and suggest that you do with its stocks.
CLGN reached its all-time high on Aug 11, 2015 with the price of 27.85 USD, and its all-time low was 3.13 USD and was reached on Dec 27, 2018. View more price dynamics on CLGN chart.
See other stocks reaching their highest and lowest prices.
CLGN stock is 10.47% volatile and has beta coefficient of 0.82. Track CollPlant Biotechnologies Ltd. stock price on the chart and check out the list of the most volatile stocks — is CollPlant Biotechnologies Ltd. there?
Today CollPlant Biotechnologies Ltd. has the market capitalization of ‪44.90 M‬, it has decreased by −2.39% over the last week.
Yes, you can track CollPlant Biotechnologies Ltd. financials in yearly and quarterly reports right on TradingView.
CollPlant Biotechnologies Ltd. is going to release the next earnings report on Nov 28, 2024. Keep track of upcoming events with our Earnings Calendar.
CLGN earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.27 USD resulting in a −37.04% surprise. The estimated earnings for the next quarter are −0.28 USD per share. See more details about CollPlant Biotechnologies Ltd. earnings.
CollPlant Biotechnologies Ltd. revenue for the last quarter amounts to ‪249.00 K‬ USD, despite the estimated figure of ‪395.50 K‬ USD. In the next quarter, revenue is expected to reach ‪416.00 K‬ USD.
CLGN net income for the last quarter is ‪−4.21 M‬ USD, while the quarter before that showed ‪−4.20 M‬ USD of net income which accounts for −0.36% change. Track more CollPlant Biotechnologies Ltd. financial stats to get the full picture.
No, CLGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 75.00 employees. See our rating of the largest employees — is CollPlant Biotechnologies Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CollPlant Biotechnologies Ltd. EBITDA is ‪−17.31 M‬ USD, and current EBITDA margin is −58.49%. See more stats in CollPlant Biotechnologies Ltd. financial statements.
Like other stocks, CLGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CollPlant Biotechnologies Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CollPlant Biotechnologies Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CollPlant Biotechnologies Ltd. stock shows the sell signal. See more of CollPlant Biotechnologies Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.